Literature DB >> 9252386

The role of the Shc phosphotyrosine interaction/phosphotyrosine binding domain and tyrosine phosphorylation sites in polyoma middle T antigen-mediated cell transformation.

P A Blaikie1, E Fournier, S M Dilworth, D Birnbaum, J P Borg, B Margolis.   

Abstract

The phosphotyrosine interaction (PI)/phosphotyrosine binding (PTB) domain of Shc binds specific tyrosine-phosphorylated motifs found on activated growth factor receptors and proteins such as polyoma virus middle T antigen (MT). Phenylalanine 198 (Phe198) has been identified as a crucial residue involved in the interaction of the Shc PI/PTB with phosphopeptides. In NIH 3T3 cells expressing MT, p52 Shc carrying the F198V mutation is weakly phosphorylated and does not bind MT or Grb2. Overexpression of the PI/PTB domain alone as Shc amino acids 1-238 acted in a dominant interfering fashion blocking MT-induced transformation. However, expression of a slightly longer construct, Shc 1-260, which encompasses Tyr239/Tyr240, a novel Shc tyrosine phosphorylation site, did not block transformation. This was found to be due to the ability of Shc 1-260 to become tyrosine-phosphorylated and bind Grb2. Furthermore, full-length Shc in which Tyr239/Tyr240 had been mutated to phenylalanine did not become tyrosine-phosphorylated or bind Grb2 but did inhibit colony formation in soft agar. Conversely, p52 Shc carrying a mutation in the other tyrosine phosphorylation site, Tyr317, became heavily tyrosine-phosphorylated, bound Grb2, and gave rise to colonies in soft agar.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252386     DOI: 10.1074/jbc.272.33.20671

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  ShcA tyrosine phosphorylation sites can replace ShcA binding in signalling by middle T-antigen.

Authors:  P R Nicholson; S Empereur; H R Glover; S M Dilworth
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

Review 2.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

Review 3.  Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.

Authors:  Michele M Fluck; Brian S Schaffhausen
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

4.  Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events.

Authors:  D D Schlaepfer; K C Jones; T Hunter
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

5.  Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein.

Authors:  M J Rauh; V Blackmore; E R Andrechek; C G Tortorice; R Daly; V K Lai; T Pawson; R D Cardiff; P M Siegel; W J Muller
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

6.  ShcA and Grb2 mediate polyoma middle T antigen-induced endothelial transformation and Gab1 tyrosine phosphorylation.

Authors:  S H Ong; S Dilworth; I Hauck-Schmalenberger; T Pawson; F Kiefer
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

Review 7.  Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancer.

Authors:  Brian S Schaffhausen; Thomas M Roberts
Journal:  Virology       Date:  2008-11-20       Impact factor: 3.616

8.  ALK-activating homologous mutations in LTK induce cellular transformation.

Authors:  J Devon Roll; Gary W Reuther
Journal:  PLoS One       Date:  2012-02-09       Impact factor: 3.240

Review 9.  Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer.

Authors:  E R Andrechek; W J Muller
Journal:  Breast Cancer Res       Date:  2000-04-12       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.